You are here

  • Home
  • Archive
  • Volume 104, Issue 6
  • Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment

Article metrics

Article menu
Download PDFPDF
Clinical science
Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment

 

Online download statistics by month:

Online download statistics by month: September 2019 to September 2024

AbstractFullPdf
Sep 20195103035
Oct 20191456494438
Nov 2019669330309
Dec 20191963414
Jan 20201592413
Feb 20201642515
Mar 2020103104
Apr 202065145
May 20205826333
Jun 202011423727
Jul 20203823216
Aug 2020227185
Sep 20202872615
Oct 20203043129
Nov 2020114127
Dec 2020158129
Jan 20212631613
Feb 202121659
Mar 20213272017
Apr 2021259117
May 2021801910
Jun 202122168
Jul 20211799
Aug 2021301110
Sep 202115108
Oct 2021150149
Nov 202123789
Dec 20212341610
Jan 20221352110
Feb 2022169179
Mar 20222432316
Apr 202219984
May 2022215133
Jun 20221511910
Jul 202215973
Aug 2022336188
Sep 2022302188
Oct 2022327219
Nov 2022254165
Dec 202224263
Jan 202310982
Feb 2023264188
Mar 20231802414
Apr 202321447
May 202323421
Jun 202318456
Jul 202315673
Aug 2023173107
Sep 202321297
Oct 20231321711
Nov 202313753
Dec 202318753
Jan 202421943
Feb 202413595
Mar 202414965
Apr 2024243154
May 2024218137
Jun 202413482
Jul 202415532
Aug 20249265
Sep 202410433
Total1473117151289